The Sub-Sero Study

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 1, 2024

Primary Completion Date

December 2, 2024

Study Completion Date

December 4, 2024

Conditions
SchizophreniaPsychosis
Interventions
DRUG

Pimavanserin 34 milligrams (MG) [Nuplazid]

Daily treatment with 34 mg per os for 6 weeks. Followed by a wash-out period up to 14 days, do to the theoretical risk of corrected QT interval (QTc) prolongation. Conventional anti-psychotic treatment will be initiated only upon normal ECG.

Sponsors
All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

collaborator

GCP unit, Copenhagen University Hospital

UNKNOWN

collaborator

ACADIA Pharmaceuticals Inc.

INDUSTRY

lead

Bjorn H. Ebdrup

OTHER